CAL
HZNP

Capital Advisors Ltd’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Capital Advisors Ltd’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18
Closed -$2K – 1548
2023
Q3 		$2K Hold
18
– – ﹤0.01% 1066
2023
Q2 		$2K Hold
18
– – ﹤0.01% 1070
2023
Q1 		$2K Hold
18
– – ﹤0.01% 963
2022
Q4 		$2K Sell
18
-41
-69% -$3.4K ﹤0.01% 923
2022
Q3 		$4K Buy
+59
New +$4.12K ﹤0.01% 714
2022
Q1 		– Sell
-3
Closed – – 1330
2021
Q4 		$0 Buy
+3
New +$327 ﹤0.01% 986

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Capital Advisors Ltd's HZNP Position: Q4 2023 in Review

Capital Advisors Ltd sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 18 shares — an estimated $2K sold.

Capital Advisors Ltd first reported a position in HZNP in Q4 2021 and held it in 6 quarters. The position peaked at $4K in Q3 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Capital Advisors Ltd reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Capital Advisors Ltd sold 18 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $2K.
  • Capital Advisors Ltd first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 6 quarters.
  • Capital Advisors Ltd's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4K in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Capital Advisors Ltd's 13F filing for Q4 2023, filed 2 Feb 2024.